Despite the recognized benefits on NAFLD deriving from pharmacological administration of fibroblast growth factor 21 (FGF21), whose endogenous counterpart is a marker of liver injury, little is known about its physiology in humans. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.